Trials / Terminated
TerminatedNCT00147485
A Phase 1 Study Of An Intravenously Administered Cyclin-Dependent Kinase Inhibitor In Patients With Advanced Cancer
A Phase 1 Safety, Pharmacokinetic And Pharmacodynamic Study Of AG-024322, An Inhibitor Of Cyclin-Dependent Kinase 1, 2 And 4, Administered Intravenously Daily For 5 Days Every 3 Weeks To Patients With Advanced Cancer
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 37 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
AG-024322 may work in cancer by stopping cancer cells from multiplying. AG-024322 is and intravenous drug from a new class of drugs call cyclin-dependent kinase (CDK inhibitors). This research study is the first time that AG-024322 will be given to people.
Detailed description
The study was prematurely discontinued due to the inability of the compound to adequately differentiate from other treatment options in the clinical endpoint and necessary product profile on April 13, 2007. Safety profile was not the reason that led to the discontinuation of the program.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AG-024322 |
Timeline
- Start date
- 2004-12-01
- Primary completion
- 2007-08-01
- Completion
- 2007-08-01
- First posted
- 2005-09-07
- Last updated
- 2008-08-18
Locations
4 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00147485. Inclusion in this directory is not an endorsement.